Home › Compare › TIEKF vs ABBV
TIEKF yields 1.95% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TIEKF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TIEKF + ABBV for your $10,000?
TIE Kinetix N.V. develops, distributes, and sells software and services in the Netherlands, the United States, Germany, and France. The company offers digital supply chain solutions; and electronic document exchange solutions, such as electronic data interchange (EDI)-2-FLOW, PDF-2-FLOW, and PORTAL-2-FLOW, as well as E-Archiving. It also provides software as a service solution for exchanging business documents to companies, governmental institutions, and trading partners and suppliers, as well as artificial intelligence-powered onboarding services. In addition, the company offers AP automation solutions for buyers and suppliers to engage in smart business exchanges; pre-built connectors and standardized API integrations to connect to ERP or other systems; compliance solutions; value added network services, which enables trading partners to communicate and exchange business documents in various formats real-time using various communication protocols; electronic invoicing solutions; and consultancy services. Further, it provides FLOW Partner Automation platform that combines supply chain integration solutions, such as EDI/XML, PDF conversion, and supplier portal, as well as analytics data and dashboards for users. The company offers its solutions to business services, industry and home improvement, telecom, banking and insurance, food industry and food retail, non-food, consumer electronics, transport and logistics, office supplies, automotive, medical, and others markets directly, as well as through a network of distribution partners. TIE Kinetix N.V. was founded in 1987 and is headquartered in Breukelen, the Netherlands.
Full TIEKF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.